# Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

Source: https://onco.cc/trials/nct06955325/  
OnCo record `nct06955325` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of icotinib, ensartinib and benmelstobart in lung cancer, run by The First Affiliated Hospital of Guangzhou Medical University, not yet recruiting.

## Summary

Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations is a phase 3, randomised interventional study registered as NCT06955325 by The First Affiliated Hospital of Guangzhou Medical University, with a registry enrolment figure of 270 participants, started 2025-05 and due to reach its primary completion in 2030-12. Interventions recorded: Icotinib; Rezivertinib; Ensartinib; Benmelstobart. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Disease-Free Survival (DFS). Lung eligibility wording from the registry: "* Primary non-squamous NSCLC confirmed by pathology, with no brain metastases". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: UPLIFT
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06955325
- Phase: 3
- Setting: A Randomized, Phase III Umbrella Trial of Adjuvant Therapy Versus Observation in Completely Resected High-Risk Stage IA-IB Non-Small Cell Lung Cancer Based on Oncogenic Driver Mutations
- Sponsor: The First Affiliated Hospital of Guangzhou Medical University
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT06955325: https://clinicaltrials.gov/study/NCT06955325

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Benmelstobart](https://onco.cc/drugs/benmelstobart/), [Ensartinib](https://onco.cc/drugs/ensartinib/), [Icotinib](https://onco.cc/drugs/icotinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06955325.json